Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin

Published:October 27, 2016DOI:


      • HSR are a common adverse event in patients rechallenged with carboplatin for ROC
      • Carboplatin-PLD is associated with a lower risk of developing HSR compared to other doublets
      • Several strategies have been developed to continue platinum-based therapy in these patients.
      • Cisplatin rechallenge in patients with carboplatin HSR is a safe and feasible approach.
      • In patients treated with cisplatin without a carboplatin-related HSR, a low rate of cisplatin-related HSR has been detected.



      Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy.


      A retrospective review of all patients with platinum sensitive ROC retreated with carboplatin was performed between January 2007 and May 2016 at the Istituto Nazionale Tumori, Fondazione “G. Pascale”, Naples.


      Among 183 patients, 49 (26.8%) presented HSR to carboplatin, mainly during second line therapy. Mean number of cycles before HSR was 8 (range 3–17). G2, G3 and G4 reaction were detected in 83%, 15% and 2% of patients, respectively. In a multivariate analysis including age, hystotype, BRCA status, previous known HSR, and combination drug administered, only the type of carboplatin-based doublet used as 2nd line therapy was found to significantly affect HSR development, with a protective effect of PLD (pegylated liposomal doxorubicin) (p = 0.014, OR = 0.027). Thirty seven patients (77%) with a previous HSR to carboplatin were rechallenged with cisplatin. Treatment was generally well tolerated. 5 patients (13.1%) experienced mild HSR to cisplatin, successfully managed in all cases. 14 patients were treated with cisplatin even without a carboplatin-related HSR due to other allergies. Among these, only one developed HSR (7.1%).


      Cisplatin rechallenge is a feasible approach in patients experiencing HSR to carboplatin to maintain the beneficial effect of platinum while reducing hypersensitivity-related risks.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Covens A.
        • Carey M.
        • Bryson P.
        • et al.
        Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III or IV epithelial ovarian cancer.
        Gynecol. Oncol. 2002; 85: 71-80
        • Gore M.E.
        • Fryatt I.
        • Wiltshaw E.
        • et al.
        Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
        Gynecol. Oncol. 1990; 36: 207-211
        • Markman M.
        • Kennedy A.
        • Webster K.
        • et al.
        Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
        Gynecol. Oncol. 1997; 65: 434-436
        • Parmar M.K.
        • Ledermann J.A.
        • Colombo N.
        • et al.
        Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
        Lancet. 2003; 361: 2099-2106
        • Markman M.
        • Kennedy A.
        • Webster K.
        • et al.
        Clinical features of hypersensitivity reactions to carboplatin.
        J. Clin. Oncol. 1999; (1141-5)
        • Morgan J.S.
        • Adam S.
        • Mason M.D.
        Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma.
        Eur. J. Cancer. 1994; 30: 1205-1206
        • Hendrik A.M.
        • Simmons D.
        • Cantwell B.M.
        Allergic reactions to carboplatin.
        Ann. Oncol. 1992; 3: 239-240
        • Gadducci A.
        • Tana R.
        • Teti G.
        • et al.
        Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
        Int. J. Gynecol. Cancer. 2008; 18: 615-620
        • Syrigou E.
        • Makrilia N.
        • Koti I.
        • et al.
        Hypersensitivity reactions to antineoplastic agents: an overview.
        Anti-Cancer Drugs. 2009; 20: 1-6
        • Polyzos A.
        • Tsavaris N.
        • Kosmas C.
        • et al.
        Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
        Oncology. 2001; 61: 129-133
        • Sliesoraitis S.
        • Chikhale P.J.
        Carboplatin hypersensitivity.
        Int. J. Gynecol. Cancer. 2005; 15: 13-18
        • Navo M.
        • Kunthur A.
        • Badell L.M.
        • et al.
        Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
        Gynecol. Oncol. 2006; 103: 608-613
        • Markman M.
        • Zanotti K.
        • Kulp B.
        • et al.
        Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
        Gynecol. Oncol. Jun 2003; 89 (514–6)
        • Watanabe Y.
        • Nakai H.
        • Ueda H.
        • Nozaki K.
        • Hoshiai H.
        Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
        Int. J. Gynecol. Cancer. 2005; 15: 224-227
        • Sugimoto H.
        • Iwamoto T.
        • Murashima Y.
        • et al.
        Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers.
        Cancer Chemother. Pharmacol. 2011; 67: 415-419
        • Schwartz J.R.
        • Bandera C.
        • Bradley A.
        • et al.
        Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from women and infants hospital.
        Gynecol. Oncol. 2007; 105: 81-83
        • Moon D.H.
        • Lee J.M.
        • Noonan A.M.
        • et al.
        Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
        Br. J. Cancer. 2013; 109: 1072-1078
        • Strickland K.C.
        • Howitt B.E.
        • Shukla S.A.
        • et al.
        Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
        Oncotarget. 2016; 7: 13587-13598
        • Pujade-Lauraine E.
        • Wagner U.
        • Aavall-Lundqvist E.
        • et al.
        Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
        J. Clin. Oncol. 2010; 28: 3323-3329
        • Hesterberg P.E.
        • Banerji A.
        • Oren E.
        • et al.
        Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
        J Allergy Clin Immunol. 2009 Jun; 123: 1262-1267
        • Lee C.W.
        • Matulonis U.A.
        • Castells M.C.
        Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
        Gynecol. Oncol. 2005 Nov; 99: 393-399
        • Goldberg A.
        • Confino-Cohen R.
        • Fishman A.
        • et al.
        A modified, prolonged desensitization protocol in carboplatin allergy.
        J. Allergy Clin. Immunol. 1996; 98: 841-843
        • Markman M.
        • Hsieh F.
        • Zanotti K.
        • et al.
        Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
        J. Cancer Res. Clin. Oncol. 2004; 130: 25-28
        • Castells M.C.
        • Tennant N.M.
        • Sloane D.E.
        • et al.
        Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
        J. Allergy Clin. Immunol. 2008 Sep; 122: 574-580
        • Limsuwan T.
        • Castells M.C.
        Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity.
        Expert Opin. Drug Saf. 2010; 9: 39-53
        • Confino-Cohen I.
        • Fishman A.
        • Altaras M.
        • Goldberg A.
        • et al.
        Successful carboplatin desensitization in patients with proven carboplatin allergy.
        Cancer. 2005; 104: 640-643
        • Rose P.G.
        • Fusco N.
        • Smrekar M.
        • et al.
        Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.
        Gynecol. Oncol. 2003; 89: 429-433
        • O'Cearbhaill R.
        • Zhou Q.
        • Iasonos A.
        • et al.
        The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
        Gynecol. Oncol. 2010; 116 (326–3)
        • Robinson J.B.
        • Singh D.
        • Bodurka-Bevers D.C.
        • et al.
        Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
        Gynecol. Oncol. 2001; 82: 550-558
        • Kandel M.J.
        • Loehr A.
        • Harter P.
        • et al.
        Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity.
        Int. J. Gynecol. Cancer. 2005; 15: 780-784
        • Dizon D.S.
        • Sabbatini P.J.
        • Aghajanian C.
        • et al.
        Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
        Gynecol. Oncol. 2001; 84: 378-382
        • Callahan M.B.
        • Lachance J.A.
        • Stone R.L.
        • et al.
        Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
        Am. J. Obstet. Gynecol. 2007; 197: 199
        • Libra M.
        • Sorio R.
        • Buonadonna A.
        • et al.
        Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases.
        Tumori. 2003; 59: 311-313
        • Porzio G.
        • Marchetti P.
        • Paris I.
        • et al.
        Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin.
        Eur. J. Gynaecol. Oncol. 2002; 23: 335-336
        • Shlebak A.
        • Clark P.
        • Green J.
        Hypersensitivity and cross-reactivity to cisplatin and analogues.
        Cancer Chemother. Pharmacol. 1995; 35: 349-351
        • Gomez P.
        • Harter P.
        • Lück H.J.
        • et al.
        Carboplatin hypersensitivity does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.
        Int. J. Gynecol. Cancer. 2009; 19: 1284-1287
        • Zanotti K.M.
        • Rybicki L.A.
        • Kennedy A.W.
        • et al.
        Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
        J. Clin. Oncol. 2001; 19: 3126-3129
        • Enrique E.
        • Malek T.
        • Castelló J.V.
        • et al.
        Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin.
        Ann. Allergy Asthma Immunol. 2008; 100: 86
        • Sheperd G.M.
        Hypersensitivity reactions to chemotherapeutic drugs.
        Clin. Rev. Allergy Immunol. 2003; 24: 253-262
        • Leguy-Seguin V.
        • Jolimoy G.
        • Coudert B.
        • et al.
        Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
        J Allergy Clin Immunol. 2007; 119: 726-730
        • Ottaiano A.
        • Tambaro R.
        • Greggi S.
        • et al.
        Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
        Anticancer Res. 2003; 23: 3465-3468
        • Sloane D.
        • Govindarajulu U.
        • Harrow-Mortelliti J.
        • et al.
        Safety, costs, and efficacy of rapid drug Desensitizations to chemotherapy and monoclonal antibodies.
        J. Allergy Clin. Immunol. Pract. 2016; 4: 497-504
        • M. M.
        Hypersensitivity reactions to carboplatin.
        Gynecol. Oncol. 2002; 84 (Letter to the editor): 353
        • Jones R.
        • Ryan M.
        • Friedlander M.
        Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
        Gynecol. Oncol. 2003; 89: 112-115